Aplastic Anemia: Evaluation and Treatment
For severe/very severe aplastic anemia, prioritize hematopoietic cell transplantation (HCT) for younger patients with matched sibling or unrelated donors, while older patients or those without matched donors should receive immunosuppressive therapy (IST) with horse ATG, cyclosporine, and eltrombopag. 1
Diagnostic Evaluation
Essential Diagnostic Criteria
- Bone marrow biopsy is mandatory to confirm diagnosis—showing marrow cellularity <25% (or 25-50% with <30% residual hematopoietic cells) 1, 2
- Peripheral blood criteria (need ≥2 of the following):
- Neutrophils <0.5 × 10⁹/L (severe AA) or <0.2 × 10⁹/L (very severe AA)
- Platelets <20 × 10⁹/L
- Reticulocytes <60 × 10⁹/L 3
Critical Exclusions Before Diagnosis
Must rule out these conditions as aplastic anemia is a diagnosis of exclusion 3, 4, 2:
- Inherited bone marrow failure syndromes (use molecular cytogenomics/genetic testing)
- Hypoplastic myelodysplastic syndromes
- Paroxysmal nocturnal hemoglobinuria (PNH)
- Drug or heavy metal-induced marrow suppression
- Viral infections (hepatitis-associated AA)
- Connective tissue disorders
First-Line Treatment Algorithm
Age and Donor-Based Decision Tree
For younger patients (<40 years) with matched sibling donor:
- Proceed directly to allogeneic HCT as first-line therapy 1, 3
- This provides complete hematopoietic recovery (curative intent)
- Preferred conditioning: Fludarabine, cyclophosphamide, and ATG-based regimen 2
- GVHD prophylaxis: Cyclosporine and methotrexate 2
For younger patients with matched unrelated donor (MUD):
- Consider upfront MUD transplant for those with severe infections and readily available donor 4
- Otherwise, start with IST and reserve MUD transplant for second-line after IST failure 1
- Recent data show improved outcomes with unrelated and alternative donors, supporting earlier incorporation 3
For older patients or those without matched donors:
- Initiate triple therapy IST: Horse ATG + cyclosporine + eltrombopag 1, 3
- This combination achieves ~80% overall initial response rate 3
Immunosuppressive Therapy Protocol
The standard IST regimen consists of 1, 3:
- Horse anti-thymocyte globulin (ATG) (preferred over rabbit ATG)
- Cyclosporine (continued long-term)
- Eltrombopag (start as soon as possible after ATG administration) 5
Critical timing note: Eltrombopag should be initiated promptly after ATG, not delayed, based on evidence showing benefit of early combination therapy 5
Supportive Care Requirements
Transfusion Strategy
- Conservative approach: Maintain hemoglobin >6 g/dL in patients without comorbidities 2
- Platelet transfusions for bleeding or prophylaxis when platelets <10-20 × 10⁹/L
- Iron chelation therapy for transfusion-dependent patients 6
Antimicrobial Prophylaxis
For patients with neutropenia, the panel strongly recommends 1:
- Antibiotic prophylaxis (typically fluoroquinolone)
- Antifungal prophylaxis (azole-based)
- Prompt management of opportunistic infections 4
- Consider G-CSF for severe infections, though routine use is not recommended 5
Second-Line Treatment After IST Failure
Response assessment timeline: Wait 3-6 months before considering next-line therapy 2
Options for non-responders or relapsed patients 1, 3:
- Allogeneic HCT (matched unrelated or alternative donor)—preferred option
- Second course of IST with or without TPO-RAs
- Alternative donor transplants: Haploidentical or cord blood transplantation showing favorable results 7, 8
Special Populations
Pregnancy
- Requires specialized management approach 4
- Multidisciplinary involvement essential
Elderly Patients
- IST preferred over transplant due to transplant-related mortality risk 6
- Treatment choice based on medical fitness and comorbidities
Non-Severe AA
- Consider aggressive treatment in select cases 5
- May observe with supportive care if stable
Critical Pitfalls to Avoid
- Do not delay genetic testing—missing inherited BMF syndromes leads to inappropriate treatment
- Do not use rabbit ATG—horse ATG is superior in efficacy 3
- Do not delay eltrombopag—start immediately after ATG, not after waiting for response 5
- Do not undertransfuse—severe anemia increases infection risk and mortality
- Do not skip antimicrobial prophylaxis in neutropenic patients—infection is a leading cause of death 1
Long-Term Monitoring Concerns
Patients require lifelong surveillance for 7, 8:
- Relapse (particularly after IST)
- Clonal evolution to myelodysplastic syndrome or acute leukemia
- Secondary malignancies (especially post-transplant)
- Late transplant complications (chronic GVHD, organ dysfunction)
Quality of Evidence Note
Most recommendations are based on low or very low certainty evidence due to reliance on small, nonrandomized studies in this rare disease 1. However, the 2026 ASH guidelines represent the most comprehensive and recent evidence synthesis, incorporating 33 recommendations and 4 good practice statements developed through rigorous GRADE methodology 1.
Given the rarity and complexity of aplastic anemia, involvement of expert centers and multidisciplinary discussion is strongly recommended to optimize outcomes 4.